We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Medtronic Worth Buying as Growth Improves but Risks Stay Elevated?
Read MoreHide Full Article
Key Takeaways
Medtronic's organic growth broadened across Cardiovascular, Medical Surgical and Neuroscience.
Medtronic raised fiscal 2027 organic revenue growth guidance to 7.25%-7.75%.
Medtronic faces margin sensitivity, currency exposure and portfolio execution demands.
Medtronic plc (MDT - Free Report) is entering fiscal 2027 with broader revenue growth, higher earnings guidance and a valuation near its historical norm. Those positives improve the investment case, but they do not remove questions around margins, foreign exchange and execution.
The stock therefore sits between improving fundamentals and still-elevated operating risk. Investors have more evidence that growth is becoming durable, yet the current setup still argues for selectivity rather than an aggressive stance.
Medtronic’s Growth Case Is Getting Stronger
Fiscal 2027 first-quarter organic revenue increased 13.7%, although the extra selling week contributed about 670 basis points to growth. Cardiovascular rose 18.9% organically, Medical Surgical gained 10.2% and Neuroscience advanced 9.3%, showing that performance was not confined to one franchise.
Cardiac Ablation Solutions remained a major driver, rising 88% worldwide, while Cardiac Rhythm Management, Cranial & Spinal Technologies and Surgical also delivered solid growth. Management raised full-year organic revenue growth guidance to 7.25%-7.75% from 6.75%-7.25%, reinforcing expectations for a stronger fiscal year.
Image Source: Zacks Investment Research
MDT Still Faces Margin and Execution Risks
The margin path remains less straightforward. Product mix was unfavorable by 50 basis points in the first quarter, mainly because of Diabetes and Cardiac Ablation Solutions. Adjusted operating margin expanded only 10 basis points to 23.7% as Medtronic continued spending on commercialization, acquisitions and growth platforms.
Tariffs were a slight headwind because payments were largely offset by refunds, but management has not assumed future refunds in its outlook. Foreign exchange is expected to create a $50-$150 million revenue headwind for fiscal 2027. The planned MiniMed separation before fiscal year-end adds another execution variable.
Medtronic Trades Near Its Five-Year Median Multiple
Medtronic trades at 15.42X forward 12-month earnings, close to its five-year median of 15.72X. That level is below the cited sub-industry multiple of 16.92X, the Medical sector’s 21.30X and the S&P 500’s 20.10X.
Image Source: Zacks Investment Research
The discount offers some valuation support, but it is not large enough to make execution concerns irrelevant. With the stock already up 17.4% in the past three months, further upside may depend more on sustained growth and margin delivery than on multiple expansion.
MDT’s Earnings Outlook Supports a Hold-or-Buy Debate
Adjusted first-quarter earnings of $1.45 per share increased 15.1% year over year and beat the Zacks Consensus Estimate by 4.3%. Medtronic raised fiscal 2027 adjusted earnings guidance to $5.94-$6.00, while the consensus estimate is $5.96 for the current fiscal year and $6.36 for fiscal 2028.
Competition remains active in key growth markets. Abbott Laboratories (ABT - Free Report) reported 13.4% comparable Electrophysiology growth in second-quarter 2026, while Boston Scientific Corporation (BSX - Free Report) posted 9.1% organic Electrophysiology growth in the same period, underscoring the intensity around cardiac ablation and related technologies.
Medtronic’s Scores Favor Selectivity
The bottom line is that Medtronic’s operating picture has improved enough to support continued interest, but the risk-reward balance is not one-sided. Better revenue breadth and a firmer earnings outlook are offset by margin sensitivity, currency exposure and portfolio execution demands.
The stock currently carries a Zacks Rank #3 (Hold). Its Value Score of B and VGM Score of B are favorable, while the Growth Score of C and Momentum Score of C are more neutral. Because Zacks Style Scores are designed to complement the Zacks Rank, that combination supports a patient stance while investors watch whether stronger growth translates into more durable earnings and margin progress.
View the Zacks #1 Rank List
Image: Bigstock
Is Medtronic Worth Buying as Growth Improves but Risks Stay Elevated?
Key Takeaways
Medtronic plc (MDT - Free Report) is entering fiscal 2027 with broader revenue growth, higher earnings guidance and a valuation near its historical norm. Those positives improve the investment case, but they do not remove questions around margins, foreign exchange and execution.
The stock therefore sits between improving fundamentals and still-elevated operating risk. Investors have more evidence that growth is becoming durable, yet the current setup still argues for selectivity rather than an aggressive stance.
Medtronic’s Growth Case Is Getting Stronger
Fiscal 2027 first-quarter organic revenue increased 13.7%, although the extra selling week contributed about 670 basis points to growth. Cardiovascular rose 18.9% organically, Medical Surgical gained 10.2% and Neuroscience advanced 9.3%, showing that performance was not confined to one franchise.
Cardiac Ablation Solutions remained a major driver, rising 88% worldwide, while Cardiac Rhythm Management, Cranial & Spinal Technologies and Surgical also delivered solid growth. Management raised full-year organic revenue growth guidance to 7.25%-7.75% from 6.75%-7.25%, reinforcing expectations for a stronger fiscal year.
Image Source: Zacks Investment Research
MDT Still Faces Margin and Execution Risks
The margin path remains less straightforward. Product mix was unfavorable by 50 basis points in the first quarter, mainly because of Diabetes and Cardiac Ablation Solutions. Adjusted operating margin expanded only 10 basis points to 23.7% as Medtronic continued spending on commercialization, acquisitions and growth platforms.
Tariffs were a slight headwind because payments were largely offset by refunds, but management has not assumed future refunds in its outlook. Foreign exchange is expected to create a $50-$150 million revenue headwind for fiscal 2027. The planned MiniMed separation before fiscal year-end adds another execution variable.
Medtronic Trades Near Its Five-Year Median Multiple
Medtronic trades at 15.42X forward 12-month earnings, close to its five-year median of 15.72X. That level is below the cited sub-industry multiple of 16.92X, the Medical sector’s 21.30X and the S&P 500’s 20.10X.
Image Source: Zacks Investment Research
The discount offers some valuation support, but it is not large enough to make execution concerns irrelevant. With the stock already up 17.4% in the past three months, further upside may depend more on sustained growth and margin delivery than on multiple expansion.
MDT’s Earnings Outlook Supports a Hold-or-Buy Debate
Adjusted first-quarter earnings of $1.45 per share increased 15.1% year over year and beat the Zacks Consensus Estimate by 4.3%. Medtronic raised fiscal 2027 adjusted earnings guidance to $5.94-$6.00, while the consensus estimate is $5.96 for the current fiscal year and $6.36 for fiscal 2028.
Competition remains active in key growth markets. Abbott Laboratories (ABT - Free Report) reported 13.4% comparable Electrophysiology growth in second-quarter 2026, while Boston Scientific Corporation (BSX - Free Report) posted 9.1% organic Electrophysiology growth in the same period, underscoring the intensity around cardiac ablation and related technologies.
Medtronic’s Scores Favor Selectivity
The bottom line is that Medtronic’s operating picture has improved enough to support continued interest, but the risk-reward balance is not one-sided. Better revenue breadth and a firmer earnings outlook are offset by margin sensitivity, currency exposure and portfolio execution demands.
The stock currently carries a Zacks Rank #3 (Hold). Its Value Score of B and VGM Score of B are favorable, while the Growth Score of C and Momentum Score of C are more neutral. Because Zacks Style Scores are designed to complement the Zacks Rank, that combination supports a patient stance while investors watch whether stronger growth translates into more durable earnings and margin progress.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.